Brinzolamide: efficacy, safety and role in the management of glaucoma

Author: Shoji, Nobuyuki

Source: Expert Review of Ophthalmology, Volume 2, Number 5, October 2007 , pp. 695-704(10)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Brinzolamide is indicated for the reduction of intraocular pressure (IOP) in eyes with ocular hypertension or open-angle glaucoma. Brinzolamide is an effective inhibitor of carbonic anhydrase and lowers IOP by suppressing formation of aqueous humor in the eye. It is formulated as a 1% ophthalmic suspension, with a recommended dosing frequency of three times daily in USA and twice daily in many other locations, including the EU and Japan. The goals of this article are to summarize the preclinical data pertaining to brinzolamide, to review safety and efficacy data from Phase III and Phase IV clinical trials, and to describe the role of brinzolamide in the management of glaucoma.

Keywords: brinzolamide; intraocular pressure; glaucoma

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17469899.2.5.695

Publication date: 2007-10-01

More about this publication?

Expert Review of Ophthalmology provides an important platform for commentary and debate on current and emerging approaches in ocular medicine.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites